Biocon Profit Triples As ‘Very Attractive’ Biosimilar Opportunities Eyed
This article was originally published in PharmAsia News
Executive Summary
Biocon, India’s biggest biotechnology firm, says its quarterly net profit tripled from a year ago, driven by a one-off IPO gain, and that it is on track to make regulatory filings for several biosimilars in the US and European markets during the next fiscal year.